Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 27Genitourinary 19Gastrointestinal 12Breast 12CNS 7Thoracic 6Tumor-Agnostic 5Sarcoma 4Head & Neck 4Other solid neoplasm 2Endocrine 1Dermatologic 1

Conditions

Advanced Solid Tumor, Adult 1Advanced Solid Tumor 1

Interventions

pembrolizumab 75Injections 67Carboplatin 38Pemetrexed 29Cisplatin 29Nivolumab 27Specimen Handling 24Interviews as Topic 24Cyclophosphamide 24atezolizumab 21tislelizumab 20Bevacizumab 20Paclitaxel 19Standard of Care 16Practice Guidelines as Topic 16fludarabine 15Docetaxel 15toripalimab 14Ipilimumab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
niraparib × Other solid neoplasm × 1 year × Clear all
NCT04972110 2025-10-30

ATTACC

Repare Therapeutics

Phase 1/2 Terminated
156 enrolled 19 charts
Other solid neoplasm

Advanced Solid Tumor, Adult

NCT06682780 2025-09-25

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

LaNova Medicines Limited

Phase 1/2 Recruiting
320 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡